Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2014 | Research article

Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings

Authors: Susan Arentz, Jason Anthony Abbott, Caroline Anne Smith, Alan Bensoussan

Published in: BMC Complementary Medicine and Therapies | Issue 1/2014

Abstract

Background

Polycystic ovary syndrome (PCOS) is a prevalent, complex endocrine disorder characterised by polycystic ovaries, chronic anovulation and hyperandrogenism leading to symptoms of irregular menstrual cycles, hirsutism, acne and infertility. Evidence based medical management emphasises a multidisciplinary approach for PCOS, as conventional pharmaceutical treatment addresses single symptoms, may be contra-indicated, is often associated with side effects and not effective in some cases. In addition women with PCOS have expressed a strong desire for alternative treatments. This review examines the reproductive endocrine effects in PCOS for an alternative treatment, herbal medicine. The aim of this review was to identify consistent evidence from both pre-clinical and clinical research, to add to the evidence base for herbal medicine in PCOS (and associated oligo/amenorrhoea and hyperandrogenism) and to inform herbal selection in the provision clinical care for these common conditions.

Methods

We undertook two searches of the scientific literature. The first search sought pre-clinical studies which explained the reproductive endocrine effects of whole herbal extracts in oligo/amenorrhoea, hyperandrogenism and PCOS. Herbal medicines from the first search informed key words for the second search. The second search sought clinical studies, which corroborated laboratory findings. Subjects included women with PCOS, menstrual irregularities and hyperandrogenism.

Results

A total of 33 studies were included in this review. Eighteen pre-clinical studies reported mechanisms of effect and fifteen clinical studies corroborated pre-clinical findings, including eight randomised controlled trials, and 762 women with menstrual irregularities, hyperandrogenism and/or PCOS. Interventions included herbal extracts of Vitex agnus-castus, Cimicifuga racemosa, Tribulus terrestris, Glycyrrhiza spp., Paeonia lactiflora and Cinnamomum cassia. Endocrine outcomes included reduced luteinising hormone (LH), prolactin, fasting insulin and testosterone. There was evidence for the regulation of ovulation, improved metabolic hormone profile and improved fertility outcomes in PCOS. There was evidence for an equivalent effect of two herbal medicines and the pharmaceutical agents bromocriptine (and Vitex agnus-castus) and clomiphene citrate (and Cimicifuga racemosa). There was less robust evidence for the complementary combination of spirinolactone and Glycyrrhiza spp. for hyperandrogenism.

Conclusions

Preclinical and clinical studies provide evidence that six herbal medicines may have beneficial effects for women with oligo/amenorrhea, hyperandrogenism and PCOS. However the quantity of pre-clinical data was limited, and the quality of clinical evidence was variable. Further pre-clinical studies are needed to explain the effects of herbal medicines not included in this review with current clinical evidence but an absence of pre-clinical data.

Available only for authorised users

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010, 25 (2): 544-551. 10.1093/humrep/dep399.PubMed

Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ, Costello MF, Guideline Development Groups: Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011, 195 (6): 65-10.5694/mja11.10915.

ESHRE: Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012, 27 (1): 14-24.

Messinis IE: Ovulation induction: a mini review. Hum Reprod. 2005, 20 (10): 2688-2697. 10.1093/humrep/dei128.PubMed

Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH: Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010, 1: 2-12.

Sills ES, Perloe M, Tucker MJ, Kaplan CR, Genton MG, Schattman GL: Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC Womens Health. 2001, 1 (1): 3-10.1186/1472-6874-1-3.PubMedPubMedCentral

Holden S, Davis R, Yeh G: Pregnant Women’s Use of Complementary & Alternative Medicine in the United States. J Alternative Compl Med. 2014, 20 (5): A120-

Lunny CA, Fraser SN: The Use of Complementary and Alternative Medicines Among a Sample of Canadian Menopausal‒Aged Women. J Midwifery Womens Health. 2010, 55 (4): 335-343. 10.1016/j.jmwh.2009.10.015.PubMed

Bishop JL, Northstone K, Green JR, Thompson EA: The use of complementary and alternative medicine in pregnancy: data from the Avon Longitudinal Study of Parents and Children (ALSPAC). Complement Ther Med. 2011, 19 (6): 303-310. 10.1016/j.ctim.2011.08.005.PubMed

10.

Nordeng H, Bayne K, Havnen GC, Paulsen BS: Use of herbal drugs during pregnancy among 600 Norwegian women in relation to concurrent use of conventional drugs and pregnancy outcome. Complement Ther Clin Pract. 2011, 17 (3): 147-151. 10.1016/j.ctcp.2010.09.002.PubMed

11.

Smith CA, Bateson DJ, Weisberg E: A survey describing the use of complementary therapies and medicines by women attending a family planning clinic. BMC Complement Altern Med. 2013, 13 (1): 224-10.1186/1472-6882-13-224.PubMedPubMedCentral

12.

Stankiewicz M, Smith C, Alvino H, Norman R: The use of complementary medicine and therapies by patients attending a reproductive medicine unit in South Australia: a prospective survey. Aust New Zeal J Obstet Gynaecol. 2007, 47 (2): 145-149. 10.1111/j.1479-828X.2007.00702.x.

13.

Ren MQ, Kuhn G, Wegner J, Chen J: Isoflavones, substances with multi-biological and clinical properties. Eur J Nutr. 2001, 40 (4): 135-146. 10.1007/PL00007388.PubMed

14.

Whitten PL, Naftolin F: Reproductive actions of phytoestrogens. Baillieres Clin Endocrinol Metab. 1998, 12 (4): 667-690. 10.1016/S0950-351X(98)80010-4.PubMed

15.

Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, Kushi LH, Erdmann C, Hiatt RA, Rybak ME, Calafat AM: Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls. Environ Health Perspect. 2010, 118 (7): 1039-1046. 10.1289/ehp.0901690.PubMedPubMedCentral

16.

Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y: A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012, 166 (1): 99-105. 10.1530/EJE-11-0616.PubMed

17.

Francis G, Kerem Z, Makkar HPS, Becker K: The biological action of saponins in animal systems: a review. Br J Nutr. 2002, 88 (6): 587-605. 10.1079/BJN2002725.PubMed

18.

Grant P, Ramasamy S: An Update on Plant Derived Anti-Androgens. Int J Endocrinol Metabol. 2012, 2012 (2, Spring): 497-502.

19.

Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet. 2007, 370 (9588): 685-697. 10.1016/S0140-6736(07)61345-2.PubMed

20.

ESHRE: Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008, 23 (3): 462-477.

21.

Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E: Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009, doi:10.1002/14651858.CD002249.pub4

22.

Polson D, Kiddy DS, Mason HD, Franks S: Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and nonresponders. Fertil Steril. 1989, 51 (1): 30-34.PubMed

23.

Kousta E, White D, Franks S: Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997, 3 (4): 359-365. 10.1093/humupd/3.4.359.PubMed

24.

Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH: Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006, 21 (1): 80-89.PubMed

25.

Williamson E: Synergy and other interactions in phytomedicines. Phytomedicine. 2001, 8 (5): 401-409. 10.1078/0944-7113-00060.PubMed

26.

Mills S, Bone K: Principles and Practice of Phytotherapy. 2000, London, England: Churchill Livingstone Harcourt Publishers

27.

Wardle JL, Adams J, Lui C-W: A qualitative study of naturopathy in rural practice: A focus upon naturopaths’ experiences and perceptions of rural patients and demands for their services. BMC Health Serv Res. 2010, 10 (1): 185-10.1186/1472-6963-10-185.PubMedPubMedCentral

28.

Steel A, Wardle J, Diezel H, Johnstone K, Adams J: Educating for collaboration: The outcomes of an interprofessional education workshop for complementary and alternative maternity care providers. Adv Integr Med. 2014, 1 (1): 17-24. 10.1016/j.aimed.2013.05.001.

29.

Teede H, Gibson-Helm M, Norman RJ, Boyle J: Polycystic Ovary Syndrome: Perceptions and Attitudes of Women and Primary Health Care Physicians on Features of PCOS and Renaming the Syndrome. J Clin Endocrinol Metabol. 2013, 99 (1): E107-E111.

30.

ESHRE: Revised 2003 consensus on diagnostic criteria and long-term health risks associated with polycystic ovary syndrome. Fertil Steril. 2004, 81 (1): 19-25.

31.

Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol. 2007, 196 (4): 402.e1-402.e11.

32.

Conway G, Honour J, Jacobs H: Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf). 1989, 30 (4): 459-470. 10.1111/j.1365-2265.1989.tb00446.x.

33.

Balen AH, Tan SL, Jacobs HS: Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage. BJOG. 1993, 100 (12): 1082-1089. 10.1111/j.1471-0528.1993.tb15170.x.

34.

Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metabol. 1999, 84 (1): 165-169.

35.

Luciano A, Chapler F, Sherman B: Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril. 1984, 41 (5): 719-725.PubMed

36.

Jarry H, Spengler B, Porzel A, Schmidt J, Wuttke W, Christoffel V: Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med. 2003, 69 (10): 945-946.PubMed

37.

Jarry H, Harnischfeger G, Düker E: Studies on the endocrine effects of the contents of Cimicifuga racemosa. In vitro binding of compounds to estrogen receptors. Planta Med. 1985, 51 (4): 316-10.1055/s-2007-969500.PubMed

38.

Jarry H, Spengler B, Wuttke W, Christoffel V: In vitro assays for bioactivity-guided isolation of endocrine active compounds in Vitex agnus-castus. Maturitas. 2006, 55: S26-S36.

39.

Jarry H, Leonhardt S, Gorkow C, Wuttke W: In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol Diabetes. 2009, 102 (06): 448-454.

40.

Meier B, Berger D, Hoberg E, Sticher O, Schaffner W: Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine. 2000, 7 (5): 373-381. 10.1016/S0944-7113(00)80058-6.PubMed

41.

Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R: Agnus-castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993, 25 (5): 253-255. 10.1055/s-2007-1002090.PubMed

42.

Sun WS, Imai A, Tagami K, Sugiyama M, Furui T, Tamaya T: In vitro stimulation of granulosa cells by a combination of different active ingredients of unkei-to. Am J Chin Med. 2004, 32 (4): 569-578. 10.1142/S0192415X0400220X.PubMed

43.

Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlová-Wuttke D: Chaste tree (Vitex agnus-castus). Pharmacology and clinical indications. Phytomedicine. 2003, 10 (4): 348-357. 10.1078/094471103322004866.PubMed

44.

Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G: Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. 2002, 80 (1): 125-130. 10.1016/S0960-0760(01)00178-9.PubMed

45.

Düker EM, Kopanski L, Jarry H, Wuttke W: Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med. 1991, 57 (5): 420-424. 10.1055/s-2006-960139.PubMed

46.

Dehghan A, Esfandiari A, Bigdeli SM: Alternative Treatment of Ovarian Cysts with Tribulus terrestris Extract: A Rat Model. Reprod Domest Anim. 2012, 47 (1): e12-e15. 10.1111/j.1439-0531.2011.01877.x.PubMed

47.

Esfandiari A, Dehghan A, Sharifi S, Najafi B, Vesali E: Effect of Tribulus terrestris extract on ovarian activity in immature Wistar rat: a histological evaluation. J Anim Vet Adv. 2011, 10 (7): 883-886.

48.

Heibashy M, Mazen G, Shahin M: Metabolic Changes and Hormonal Disturbances in Polycystic Ovarian Syndrome Rats and the Amelioration Effects of Metformin and/or Cinnamon Extraction. J Am Sci. 2013, 9 (12): p54-p62.

49.

Ibrahim N, Shalaby AS, Farag RS, Elbaroty GS, Nofal SM, Hassan EM: Gynecological efficacy and chemical investigation of Vitex agnus-castus L. fruits growing in Egypt. Nat Prod Res. 2008, 22 (6): 537-546. 10.1080/14786410701592612.PubMed

50.

Lee JC, Pak SC, Lee SH, Lim SC, Bai YH, Jin CS, Kim JS, Na CS, Bae CS, Oh KS: The effect of herbal medicine on nerve growth factor in estradiol valerate-induced polycystic ovaries in rats. Am J Chin Med. 2003, 31 (06): 885-895. 10.1142/S0192415X03001636.PubMed

51.

Martino-Andrade AJ, Morais RN, Spercoski KM, Rossi SC, Vechi MF, Golin M, Lombardi NF, Greca CS, Dalsenter PR: Effects of Tribulus terrestris on endocrine sensitive organs in male and female Wistar rats. J Ethnopharmacol. 2010, 127 (1): 165-170. 10.1016/j.jep.2009.09.031.PubMed

52.

Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W: Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol. 2003, 149 (4): 351-362. 10.1530/eje.0.1490351.PubMed

53.

Takeuchi T, Nishii O, Okamura T, Yaginuma T: Effect of traditional herbal medicine, shakuyaku-kanzo-to on total and free serum testosterone levels. Am J Chin Med. 1989, 17 (1-2): 35-44.PubMed

54.

Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P: Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007, 131 (1): 61-67. 10.1016/j.ejogrb.2006.10.013.PubMed

55.

Armanini D, Mattarello MJ, Fiore C, Bonanni G, Scaroni C, Sartorato P, Palermo M: Licorice reduces serum testosterone in healthy women. Steroids. 2004, 69 (11–12): 763-766.PubMed

56.

Milanov S, Maleeva A, Tashkov M: Tribestan effect on the concentration of some hormones in the serum of healthy subjects. 1981, Sofia, Bulgaria: Company documentation, Chemical Pharmaceutical Research Institute

57.

Ushiroyama T, Ikeda A, Sakai M, Hosotani T, Suzuki Y, Tsubokura S, Ueki M: Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion. J Reprod Med. 2001, 46 (5): 451-456.PubMed

58.

Yaginuma TI, Yasui R, Arai H, Kawabata T: Effect of traditional herbal medicine on serum testosterone levels and its induction of regular ovulation in hyperandrogenic and oligomenorrheic women. Nippon Sanka Fujinka Gakkai Zasshi. 1982, 34 (7): 939-PubMed

59.

Takahashi K, Kitao M: Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease. Int J Fertil Menopausal Stud. 1994, 39 (2): 69-PubMed

60.

Tabakova P, Dimitrov M, Tashkov B: Clinical studies on the preparation Tribestan in women with endocrine infertility or menopausal syndrome. 1984, Sofia, Bulgaria: 1st Obstetrical and Gynecological Hospital

61.

Gerhard I, Patek A, Monga B, Blank A, Gorkow C: Mastodynon® for Female Infertility. Randomized placebo controlled, clinical double-blind study. Forschende Komplementärmedizin/Res Compl Med. 1998, 5 (6): 272-278.

62.

Bergmann J, Luft B, Boehmann S, Runnebaum B, Gerhard I: The efficacy of the complex medication Phyto-Hypophyson L in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study. Forschende Komplementärmedizin und klassische Naturheilkunde. Res Compl Nat Classical Med. 2000, 7 (4): 190-

63.

Kilicdag E, Tarim E, Bagis T, Erkanli S, Aslan E, Ozsahin K, Kuscu E: Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynecol Obstet. 2004, 85 (3): 292-293. 10.1016/j.ijgo.2004.01.001.

64.

Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, Schmitz H: Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittel-Forschung (Drug Res). 1993, 64 (7): 752-756.

65.

Shahin AY, Ismail AM, Zahran KM, Makhlouf AM: Adding phytoestrogens to clomiphene induction in unexplained infertility patients – a randomized trial. Reprod Biomed Online. 2008, 16 (4): 580-588. 10.1016/S1472-6483(10)60465-8.PubMed

66.

Wang JG, Anderson RA, Graham GM, Chu MC, Sauer MV, Guarnaccia MM, Lobo RA: The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril. 2007, 88 (1): 240-243. 10.1016/j.fertnstert.2006.11.082.PubMed

67.

Kamel HH: Role of phyto-oestrogens in ovulation induction in women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2013, 168 (1): 60-63. 10.1016/j.ejogrb.2012.12.025.PubMed

68.

Shahin AY, Mohammed SA: Adding the phytoestrogen Cimicifugae Racemosae to clomiphene induction cycles with timed intercourse in polycystic ovary syndrome improves cycle outcomes and pregnancy rates-a randomized trial. Gynecol Endocrinol. 2014, 30 (7): 505-510. 10.3109/09513590.2014.895983.PubMed

69.

Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W: In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas. 2003, 44 (Supplement 1): S31-S38.PubMed

70.

Webster D, Lu J, Chen SN, Farnsworth NR, Wang ZJ: Activation of the μ-opiate receptor by Vitex agnus-castus methanol extracts: Implication for its use in PMS. J Ethnopharmacol. 2006, 106 (2): 216-221. 10.1016/j.jep.2005.12.025.PubMed

71.

Chan CC, Koo MW, Ng EH, Tang OS, Yeung WS, Ho PC: Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome—a randomized placebo-controlled trial. J Soc Gynecol Investig. 2006, 13 (1): 63-68. 10.1016/j.jsgi.2005.10.006.PubMed

72.

Kao Y-H, Hiipakka RA, Liao S: Modulation of endocrine systems and food intake by green tea epigallocatechin gallate 1. Endocrinology. 2000, 141 (3): 980-987.PubMed

73.

Akdoğan M, Tamer MN, Cüre E, Cüre MC, Köroğlu BK, Delibaş N: Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytother Res. 2007, 21 (5): 444-447. 10.1002/ptr.2074.PubMed

74.

Grant P: Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010, 24 (2): 186-188.PubMed

75.

Kudolo GB, Wang W, Javors M, Blodgett J: The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects–A double blind placebo-controlled, crossover study. Clin Nutr. 2006, 25 (4): 606-616. 10.1016/j.clnu.2005.12.012.PubMed

76.

Chen J-T, Tominaga K, Sato Y, Anzai H, Matsuoka R: Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Alternative Compl Med. 2010, 16 (12): 1295-1299. 10.1089/acm.2009.0696.

77.

Phipps WR, Martini MC, Lampe JW, Slavin JL, Kurzer MS: Effect of flax seed ingestion on the menstrual cycle. (J Clin Endocrinol Metabo. 1993, 77 (5): 1215-1219.

78.

Lampe J, Martini MC, Kurzer MS, Adlercreutz H, Slavin JL: Urinary lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. Am J Clin Nutr. 1994, 60 (1): 122-128.PubMed

79.

Hutchins AM, Martini MC, Olson BA, Thomas W, Slavin JL: Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. Nutr Cancer. 2001, 39 (1): 58-65. 10.1207/S15327914nc391_8.PubMed

80.

Frische EJ, Hutchins AM, Martini MC, Thomas W, Slavin JL: Effect of flaxseed and wheat bran on serum hormones and lignan excretion in premenopausal women. J Am Coll Nutr. 2003, 22 (6): 550-554. 10.1080/07315724.2003.10719335.PubMed

81.

Melo E, Bertero EB, Rios LA, Mattos D: Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol. 2002, 28 (5): 418-425.PubMed

82.

Yang J, Te AE: Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2005, 6 (4): 290-295. 10.1007/s11934-005-0026-1.PubMed

83.

Morgia G, Mucciardi G, Madonia M, Castelli T, Favilla V, Magno C: Treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with Serenoa repens plus selenio and licopene (Profluss®): a randomized multicenter placebo-controlled study. J Urol. 2008, 179 (4): 32-

84.

Casner PR, Bent S, Kane C, Shinohara K: Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006, 354 (18): 1950-1951.PubMed

85.

Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M: The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double‒blind, placebo‒controlled, clinical trial. Phytother Res. 2006, 20 (12): 1036-1039. 10.1002/ptr.1988.PubMed

86.

Jalilian N, Modarresi M, Rezaie M, Ghaderi L, Bozorgmanesh M: Phytotherapeutic Management of Polycystic Ovary Syndrome: Role of Aerial Parts of Wood Betony (Stachys lavandulifolia). Phytother Res. 2013, 27 (11): 1708-1713. 10.1002/ptr.4921.PubMed

87.

Najafipour F, Rahimi AO, Mobaseri M, Agamohamadzadeh N, Nikoo A, Aliasgharzadeh A: Therapeutic effects of stinging nettle (Urtica dioica) in women with Hyperandrogenism. Int J Current Res Acad Rev. 2014, 2 (7): 153-160.

88.

Hryb D, Khan MS, Romas NA, Rosner W: The effect of extracts of the roots of the stinging nettle. Planta Med. 1995, 61 (01): 31-32. 10.1055/s-2006-957993.PubMed

89.

Schöttner M, Ganßer D, Spiteller G: Lignans from the Roots of Urtica spp. Planta Med. 1997, 63 (06): 529-532. 10.1055/s-2006-957756.PubMed

90.

Zhang Q, Li L, Liu L, Li Y, Yuan L, Song L, Wu Z: Effects of the polysaccharide fraction of Urtica fissa on castrated rat prostate hyperplasia induced by testosterone propionate. Phytomedicine. 2008, 15 (9): 722-727. 10.1016/j.phymed.2007.12.005.PubMed

91.

Hajhashemi V, Klooshani V: Antinociceptive and anti-inflammatory effects of Urtica dioica leaf extract in animal models. Avicenna J Phytomedicine. 2013, 3 (2): 193-200.

92.

Loch E, Böhnert K, Peeters M: The treatment of menstrual disorders with Vitex agnus-castus tincture. Der Frauenarzt. 1991, 32 (8): 867-870.

93.

Loch E, Selle H, Boblitz N: Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000, 9 (3): 315-320. 10.1089/152460900318515.PubMed

94.

Ma L, Lin S, Chen R, Zhang Y, Chen F, Wang X: Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust New Zeal J Obstet Gynaecol. 2010, 50 (2): 189-193. 10.1111/j.1479-828X.2010.01137.x.

95.

Schellenberg R: Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ (Clin Res ed). 2001, 134-137.

96.

Lauritzen CH, Reuter HD, Repges R, Böhnert KJ, Schmidt U: Treatment of premenstrual tension syndrome with Vitex agnus castus controlled, double-blind study versus pyridoxine. Phytomedicine. 1997, 4 (3): 183-189. 10.1016/S0944-7113(97)80066-9.PubMed

97.

He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S, Yao Y, Lu J, Lin S: Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009, 63 (1): 99-103. 10.1016/j.maturitas.2009.01.006.PubMed

98.

Wuttke W, Splitt G, Gorkow C, Sieder C: Treatment of cyclical mastalgia: Results of a randomised, placebo- controlled, double-blind study: Objective. Obstet Gynecol. 1997, 57 (10): 569-574.

99.

Halaska M, Beles P, Gorkow C, Sieder C: Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999, 8 (4): 175-181. 10.1054/brst.1999.0039.PubMed

100.

Wuttke W, Seidlova-Wuttke D, Gorkow C: The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. 2003, 44: S67-S77.PubMed

101.

Yamada K, Kanba S, Yagi G, Asai M: Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. J Clin Psychopharmacol. 1999, 19 (4): 380-10.1097/00004714-199908000-00018.PubMed

102.

Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang HK, Itokawa H, Su CY, Shih C, Chiang T, Chang E: Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem. 2002, 45 (23): 5037-5042. 10.1021/jm020200g.PubMed

103.

Zangeneh FZ, Minaee B, Amirzargar A, Ahangarpour A, Mousavizadeh K: Effects of chamomile extract on biochemical and clinical parameters in a rat model of polycystic ovary syndrome. J Reprod Infertil. 2010, 11 (3): 169-

104.

Akdogan M, Ozguner M, Kocak A, Oncu M, Cicek E: Effects of peppermint teas on plasma testosterone, follicle-stimulating hormone, and luteinizing hormone levels and testicular tissue in rats. Urology. 2004, 64 (2): 394-398. 10.1016/j.urology.2004.03.046.PubMed

105.

Gebhardt R: Antioxidative, antiproliferative and biochemical effects in HepG2 cells of a homeopathic remedy and its constituent plant tinctures tested separately or in combination. Arzneimittel Forschung. 2003, 53 (12): 823-830.PubMed

106.

Burdette JE, Liu J, Chen S, Fabricant DS, Piersen CE, Barker EL, Pezzuto JM, Mesecar A, van Breemen RB, Farnsworth NR: Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003, 51 (19): 5661-5670. 10.1021/jf034264r.PubMed

107.

Whitehead SA, Lacey M: Phytoestrogens inhibit aromatase but not 17β hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa luteal cells: evidence for FSH induction of 17β HSD. Hum Reprod. 2003, 18 (3): 487-494. 10.1093/humrep/deg125.PubMed

108.

Zhao L, Li W, Han F, Hou L, Baillargeon J-P, Kuang H, Wang Y, Wu X: Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril. 2011, 95 (1): 461-463. 10.1016/j.fertnstert.2010.07.1090.PubMed

109.

Kostova I, Dinchev D: Saponins in Tribulus terrestris - Chemistry and bioactivity. Phytochem Rev. 2005, 4 (2–3): 111-137.

110.

Takeuchi T, Nishii O, Okamura T, Yaginuma T: Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. Am J Chin Med. 1991, 19 (1): 73-78. 10.1142/S0192415X91000119.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/511/prepub

Title: Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings
Authors: Susan Arentz
Jason Anthony Abbott
Caroline Anne Smith
Alan Bensoussan
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2014
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/1472-6882-14-511

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Alternative and antioxidant therapies used by a sample of infertile males in Jordan: a cross-sectional survey

Nigella Sativa reverses osteoporosis in ovariectomized rats

Use of herbal medicine during pregnancy among women with access to public healthcare in Nairobi, Kenya: a cross-sectional survey

Anti-hyperglycemic activity of Centella asiatica is partly mediated by carbohydrase inhibition and glucose-fiber binding

Dendropanax morbifera Léveille extract facilitates cadmium excretion and prevents oxidative damage in the hippocampus by increasing antioxidant levels in cadmium-exposed rats

NK cells mediate the cumulative analgesic effect of electroacupuncture in a rat model of neuropathic pain